171 related articles for article (PubMed ID: 37743012)
1. The Origin and Fate of Liver Myofibroblasts.
Kim HY; Sakane S; Eguileor A; Carvalho Gontijo Weber R; Lee W; Liu X; Lam K; Ishizuka K; Rosenthal SB; Diggle K; Brenner DA; Kisseleva T
Cell Mol Gastroenterol Hepatol; 2024; 17(1):93-106. PubMed ID: 37743012
[TBL] [Abstract][Full Text] [Related]
2. The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis.
Karin D; Koyama Y; Brenner D; Kisseleva T
Differentiation; 2016 Sep; 92(3):84-92. PubMed ID: 27591095
[TBL] [Abstract][Full Text] [Related]
3. Molecular and cellular mechanisms of liver fibrosis and its regression.
Kisseleva T; Brenner D
Nat Rev Gastroenterol Hepatol; 2021 Mar; 18(3):151-166. PubMed ID: 33128017
[TBL] [Abstract][Full Text] [Related]
4. What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis.
Iwaisako K; Brenner DA; Kisseleva T
J Gastroenterol Hepatol; 2012 Mar; 27 Suppl 2(Suppl 2):65-8. PubMed ID: 22320919
[TBL] [Abstract][Full Text] [Related]
5. The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies.
Xu J; Liu X; Koyama Y; Wang P; Lan T; Kim IG; Kim IH; Ma HY; Kisseleva T
Front Pharmacol; 2014; 5():167. PubMed ID: 25100997
[TBL] [Abstract][Full Text] [Related]
6. Origin of myofibroblasts in the fibrotic liver in mice.
Iwaisako K; Jiang C; Zhang M; Cong M; Moore-Morris TJ; Park TJ; Liu X; Xu J; Wang P; Paik YH; Meng F; Asagiri M; Murray LA; Hofmann AF; Iida T; Glass CK; Brenner DA; Kisseleva T
Proc Natl Acad Sci U S A; 2014 Aug; 111(32):E3297-305. PubMed ID: 25074909
[TBL] [Abstract][Full Text] [Related]
7. Anti-fibrogenic strategies and the regression of fibrosis.
Kisseleva T; Brenner DA
Best Pract Res Clin Gastroenterol; 2011 Apr; 25(2):305-17. PubMed ID: 21497747
[TBL] [Abstract][Full Text] [Related]
8. Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts.
Liu X; Xu J; Brenner DA; Kisseleva T
Curr Pathobiol Rep; 2013 Sep; 1(3):209-214. PubMed ID: 24000319
[TBL] [Abstract][Full Text] [Related]
9. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis.
Kisseleva T; Cong M; Paik Y; Scholten D; Jiang C; Benner C; Iwaisako K; Moore-Morris T; Scott B; Tsukamoto H; Evans SM; Dillmann W; Glass CK; Brenner DA
Proc Natl Acad Sci U S A; 2012 Jun; 109(24):9448-53. PubMed ID: 22566629
[TBL] [Abstract][Full Text] [Related]
10. The origin of fibrogenic myofibroblasts in fibrotic liver.
Kisseleva T
Hepatology; 2017 Mar; 65(3):1039-1043. PubMed ID: 27859502
[TBL] [Abstract][Full Text] [Related]
11. The phenotypic fate and functional role for bone marrow-derived stem cells in liver fibrosis.
Kisseleva T; Brenner DA
J Hepatol; 2012 Apr; 56(4):965-72. PubMed ID: 22173163
[TBL] [Abstract][Full Text] [Related]
12. Origin and function of myofibroblasts in the liver.
Wells RG; Schwabe RF
Semin Liver Dis; 2015 May; 35(2):97-106. PubMed ID: 25974896
[TBL] [Abstract][Full Text] [Related]
13. Recent advancement of molecular mechanisms of liver fibrosis.
Seki E; Brenner DA
J Hepatobiliary Pancreat Sci; 2015 Jul; 22(7):512-8. PubMed ID: 25869468
[TBL] [Abstract][Full Text] [Related]
14. Effect of human amniotic epithelial cells on pro-fibrogenic resident hepatic cells in a rat model of liver fibrosis.
Cargnoni A; Farigu S; Cotti Piccinelli E; Bonassi Signoroni P; Romele P; Vanosi G; Toschi I; Cesari V; Barros Sant'Anna L; Magatti M; Silini AR; Parolini O
J Cell Mol Med; 2018 Feb; 22(2):1202-1213. PubMed ID: 29105277
[TBL] [Abstract][Full Text] [Related]
15. Fibronectin extra domain-A promotes hepatic stellate cell motility but not differentiation into myofibroblasts.
Olsen AL; Sackey BK; Marcinkiewicz C; Boettiger D; Wells RG
Gastroenterology; 2012 Apr; 142(4):928-937.e3. PubMed ID: 22202457
[TBL] [Abstract][Full Text] [Related]
16. The role of Mesothelin signaling in Portal Fibroblasts in the pathogenesis of cholestatic liver fibrosis.
Fuji H; Miller G; Nishio T; Koyama Y; Lam K; Zhang V; Loomba R; Brenner D; Kisseleva T
Front Mol Biosci; 2021; 8():790032. PubMed ID: 34966784
[TBL] [Abstract][Full Text] [Related]
17. Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression.
Caligiuri A; Gentilini A; Pastore M; Gitto S; Marra F
Cells; 2021 Oct; 10(10):. PubMed ID: 34685739
[TBL] [Abstract][Full Text] [Related]
18. Strategies to Detect Hepatic Myofibroblasts in Liver Cirrhosis of Different Etiologies.
Iwaisako K; Taura K; Koyama Y; Takemoto K; Asagiri M
Curr Pathobiol Rep; 2014; 2(4):209-215. PubMed ID: 25401051
[TBL] [Abstract][Full Text] [Related]
19. New therapies for hepatic fibrosis.
Koyama Y; Brenner DA
Clin Res Hepatol Gastroenterol; 2015 Sep; 39 Suppl 1(0 1):S75-9. PubMed ID: 26206573
[TBL] [Abstract][Full Text] [Related]
20. Inducible factors for cancer-associated fibroblasts in liver cancer versus myofibroblasts in inflammatory liver disease.
Okabe H; Hayashi H; Nakagawa S; Imai K; Nitta H; Arima K; Hashimoto D; Chikamoto A; Ishiko T; Beppu T; Baba H
Histol Histopathol; 2016 Feb; 31(2):141-8. PubMed ID: 26398776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
